Carcinoma, Non-Squamous Non-Small Cell Lung
Conditions
Brief summary
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants were randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).
Interventions
Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression.
DRUGCarboplatin
Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
DRUGNab-Paclitaxel
Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.
DRUGPemetrexed
Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eastern Cooperative Oncology Group performance status of 0 or 1 * Histologically or cytologically confirmed, Stage IV non-squamous NSCLC * Participants with no prior treatment for Stage IV non-squamous NSCLC * Previously obtained archival tumor tissue or tissue obtained from fresh biopsy at screening * Measurable disease, as defined by RECIST v1.1 * Adequate hematologic and end organ function
Exclusion criteria
Cancer-Specific Exclusions: * Active or untreated central nervous system metastases * Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome General Medical Exclusions: * Pregnant or lactating women * History of autoimmune disease * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted * Positive test for human immunodeficiency virus * Active hepatitis B or hepatitis C * Severe infection within 4 weeks prior to randomization * Significant cardiovascular disease * Illness or condition that interferes with the participant's capacity to understand, follow and/or comply with study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population | Up to approximately 35 months after first patient enrolled | PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first in the ITT-WT population. |
| Overall Survival (OS) in the ITT-WT Population | Up to approximately 35 months after first patient enrolled | OS is defined as the time between the date of randomization and date of death from any cause in the ITT-WT population. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | Up to approximately 35 months after first subject enrolled | PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation. |
| OS as Determined by the Investigator Using Recist v1.1 in the ITT Population | Up to approximately 41 months after first subject enrolled | OS is defined as the time between the date of randomization and date of death from any cause in the ITT population. |
| OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population | Up to approximately 35 months after first patient enrolled | OS is defined as the time between the date of randomization and date of death from any cause in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation. |
| Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population | Up to approximately 41 months after first subject enrolled | ORR (confirmation not required) is defined as the proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by the investigator in the ITT-WT population. |
| Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | Up to approximately 35 months after first subject enrolled | ORR (confirmation not required) is defined as proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by investigator in ITT population, PD-L1 Expression population, and PD-L1 Expression WT population. ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. PD-L1 expression WT population is defined as PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation. |
| Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population | Up to approximately 35 months after first subject enrolled | DOR,defined for participants with objective response (OR) as time from 1st documented OR to documented disease progression as determined by investigator using RECIST v1.1,or death from any cause,whichever occurs 1st.ITT defined as all randomized participants,regardless of receipt of assigned treatment.ITT-WT defined as ITT population excluding participants with activating EGFR mutation or ALK translocation.PD-L1 expression population is defined as one of following:PD-L1 IHC TC1/2/3 or IC1/2/3 population,defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue;PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue;PD-L1 IHC TC3 or IC3 population,defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue.PD-L1 expression WT is defined as PD-L1 expression population excluding participants with activating EGFR mutation or ALK translocation. |
| Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population | Up to 41 months after first patient enrolled, years 1 and 2 reported | The OS rate at the 1- and 2-year landmark time points after randomization. |
| Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population | Up to 35 months after first patient enrolled, years 1 and 2 reported | The OS rate at the 1- and 2-year landmark time points after randomization in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation. |
| Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population | Up to approximately 35 months after first subject enrolled | Defined as time from randomization to confirmed deterioration (10-point change) on the combined European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C30) and supplemental lung cancer module (EORTC QLQ-LC13) symptom subscales. |
| Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Up to approximately 35 months after first subject enrolled | Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of≥0.5 points for chest pain score is considered to be clinically significant. |
| Percentage of Participants With Adverse Events | Up to approximately 69 months after first patient enrolled | Percentage of participants with at least one adverse event. Adverse event onset date before cross over. |
| Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab | Up to approximately 35 months after first subject enrolled | Baseline prevalence and post-baseline incidence of anti-drug antibodies (ADA) to Atezolizumab in the Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B Carboplatin+nab-paclitaxel Crossover Participants |
| Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm | Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days) | Predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes. |
| Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel | Cycle 1 Day 21, Cycle 2 Day 21, Cycle 3 Day 21, and Cycle 7 Day 21 (Cycle length = 21 days) | Predose samples will be collected on the same day of treatment administration. |
| Plasma Concentrations of Carboplatin | Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 hour after carboplatin infusion (infusion duration=15 to 30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months) | — |
| Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Predose (same day of treatment administration), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after nab-paclitaxel infusion (infusion duration=30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months) | — |
Countries
Belgium, Canada, France, Germany, Israel, Italy, Spain, United States
Participant flow
Pre-assignment details
Participants in this study included: histologically or cytologically confirmed, Stage IV non-squamous NSCLC; and no prior treatment for Stage IV non-squamous NSCLC. At the time of study completion a few participants that were still on maintenance treatment with atezolizumab were moved to another study, Post-Trial Access Program, or commercial use. Therefore, the reason for discontinuation was entered Study terminated by Sponsor for these participants.
Participants by arm
| Arm | Count |
|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit. | 483 |
| Arm B (Nab-Paclitaxel+Carboplatin) Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression. | 240 |
| Total | 723 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | 3 Year Treatment Completed, Immunotherapy Paused, Continuing Follow-Up Planned | 1 | 0 |
| Overall Study | Administrative-Change Facility | 1 | 0 |
| Overall Study | Death | 330 | 176 |
| Overall Study | Death Prior First Dose | 1 | 0 |
| Overall Study | Lost to Follow-up | 1 | 2 |
| Overall Study | Non-Compliance | 1 | 0 |
| Overall Study | Patient Admitted to Hospital & Couldn't be Dosed for Randomization | 1 | 0 |
| Overall Study | Patient Moved to Commercial Atezolizumab Use | 14 | 9 |
| Overall Study | Patient Moving to Roll-Over Study | 17 | 5 |
| Overall Study | Physician Decision | 7 | 0 |
| Overall Study | Prolonged Hospitalization | 1 | 0 |
| Overall Study | Protocol Violation | 0 | 1 |
| Overall Study | Randomized in Error | 5 | 4 |
| Overall Study | Request From Sponsor to Withdraw Patient in Survival Follow-Up | 78 | 29 |
| Overall Study | Sponsor Decision | 2 | 0 |
| Overall Study | Study Terminated by Sponsor | 3 | 1 |
| Overall Study | Withdrawal by Subject | 20 | 13 |
Baseline characteristics
| Characteristic | Arm B (Nab-Paclitaxel+Carboplatin) | Total | Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) |
|---|---|---|---|
| Age, Continuous | 64.4 Years STANDARD_DEVIATION 8.9 | 64.0 Years STANDARD_DEVIATION 9.3 | 63.8 Years STANDARD_DEVIATION 9.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 12 Participants | 37 Participants | 25 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 213 Participants | 639 Participants | 426 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 15 Participants | 47 Participants | 32 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants | 17 Participants | 14 Participants |
| Race (NIH/OMB) Black or African American | 8 Participants | 26 Participants | 18 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 7 Participants | 28 Participants | 21 Participants |
| Race (NIH/OMB) White | 222 Participants | 650 Participants | 428 Participants |
| Sex: Female, Male Female | 102 Participants | 308 Participants | 206 Participants |
| Sex: Female, Male Male | 138 Participants | 415 Participants | 277 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 338 / 473 | 108 / 131 | 70 / 101 |
| other Total, other adverse events | 467 / 473 | 127 / 131 | 100 / 101 |
| serious Total, serious adverse events | 252 / 473 | 63 / 131 | 24 / 101 |
Outcome results
Primary
Overall Survival (OS) in the ITT-WT Population
OS is defined as the time between the date of randomization and date of death from any cause in the ITT-WT population.
Time frame: Up to approximately 35 months after first patient enrolled
Population: The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Overall Survival (OS) in the ITT-WT Population | 18.6 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | Overall Survival (OS) in the ITT-WT Population | 13.9 Months |
p-value: 0.029895% CI: [0.636, 0.977]Log Rank
Primary
Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first in the ITT-WT population.
Time frame: Up to approximately 35 months after first patient enrolled
Population: The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population | 7.0 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population | 5.5 Months |
p-value: <0.000195% CI: [0.536, 0.763]Log Rank
Secondary
Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale
Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of≥0.5 points for chest pain score is considered to be clinically significant.
Time frame: Up to approximately 35 months after first subject enrolled
Population: Patient-reported outcome (PRO) analysis were conducted on either the ITT-WT population or the PRO-evaluable WT population, defined as participants randomized into the ITT-WT population who completed a given PRO questionnaire at the baseline visit and at least one post-baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 20 | -0.37 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 97 | -0.31 Units on a scale | Standard Deviation 1.19 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 98 | -0.10 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 111 | -0.30 Units on a scale | Standard Deviation 0.84 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 112 | -0.63 Units on a scale | Standard Deviation 0.48 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 113 | -0.25 Units on a scale | Standard Deviation 0.65 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 114 | -0.33 Units on a scale | Standard Deviation 0.29 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 117 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 118 | -0.25 Units on a scale | Standard Deviation 0.35 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 119 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 120 | -0.25 Units on a scale | Standard Deviation 0.35 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 121 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 123 | -0.75 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 124 | 0.50 Units on a scale | — |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 112 | 0.20 Units on a scale | Standard Deviation 0.43 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 114 | 0.40 Units on a scale | Standard Deviation 0.72 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 115 | 0.80 Units on a scale | Standard Deviation 0.85 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 117 | 0.30 Units on a scale | Standard Deviation 0.14 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 118 | 0.30 Units on a scale | Standard Deviation 0.42 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 119 | 0.50 Units on a scale | Standard Deviation 0.42 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 120 | 0.30 Units on a scale | Standard Deviation 0.42 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 121 | 0.60 Units on a scale | Standard Deviation 0.57 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 122 | 0.60 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 123 | -0.20 Units on a scale | Standard Deviation 0.57 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 124 | -0.20 Units on a scale | — |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 1 | 0.41 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 2 | 0.36 Units on a scale | Standard Deviation 1.2 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 3 | 0.27 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 4 | 0.02 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 5 | 0.13 Units on a scale | Standard Deviation 1.24 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 6 | -0.09 Units on a scale | Standard Deviation 1.29 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 104 | -0.60 Units on a scale | Standard Deviation 1.39 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 114 | 0.00 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 6 | -0.15 Units on a scale | Standard Deviation 0.86 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 86 | -0.54 Units on a scale | Standard Deviation 1.27 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 95 | 0.05 Units on a scale | Standard Deviation 1.23 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 50 | 0.32 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 51 | 0.24 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 106 | -0.63 Units on a scale | Standard Deviation 0.48 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 107 | -0.63 Units on a scale | Standard Deviation 0.48 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 108 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 109 | -0.50 Units on a scale | Standard Deviation 0.5 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 110 | -0.50 Units on a scale | Standard Deviation 0.45 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 115 | 0.25 Units on a scale | Standard Deviation 0.35 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 116 | -0.25 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 4 | 0.23 Units on a scale | Standard Deviation 0.8 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 8 | 0.32 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 10 | 0.41 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 13 | 0.32 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 14 | 0.34 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 24 | 0.22 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 25 | 0.21 Units on a scale | Standard Deviation 0.88 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 27 | 0.20 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 30 | 0.24 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 35 | 0.22 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 36 | 0.21 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 37 | 0.16 Units on a scale | Standard Deviation 1.13 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 40 | 0.31 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 42 | 0.26 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 86 | -0.07 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 89 | 0.09 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 102 | 0.35 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 104 | 0.48 Units on a scale | Standard Deviation 1.22 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 105 | -0.20 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 113 | 0.20 Units on a scale | Standard Deviation 0.67 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 116 | 0.60 Units on a scale | Standard Deviation 0.57 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 125 | 0.20 Units on a scale | — |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 2 | -0.02 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 4 | -0.11 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 5 | -0.12 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 6 | -0.24 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 10 | -0.10 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 11 | -0.11 Units on a scale | Standard Deviation 1.14 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 12 | -0.15 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 15 | -0.26 Units on a scale | Standard Deviation 1.14 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 16 | -0.33 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 17 | -0.33 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 18 | -0.28 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 19 | -0.28 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 27 | -0.22 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 28 | -0.20 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 34 | -0.18 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 35 | -0.10 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 73 | -0.25 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 74 | -0.08 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 75 | -0.21 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 76 | 0.03 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 77 | -0.06 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 78 | -0.04 Units on a scale | Standard Deviation 0.84 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 79 | -0.11 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 80 | -0.18 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 81 | -0.59 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 82 | -0.39 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 83 | -0.34 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 84 | -0.20 Units on a scale | Standard Deviation 0.75 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 85 | -0.44 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 86 | -0.38 Units on a scale | Standard Deviation 0.64 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 87 | -0.53 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 88 | -0.46 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 89 | -0.55 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 90 | -0.18 Units on a scale | Standard Deviation 0.85 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 91 | -0.32 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 92 | -0.40 Units on a scale | Standard Deviation 0.66 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 93 | -0.18 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 94 | -0.30 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 95 | -0.05 Units on a scale | Standard Deviation 1.26 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 96 | -0.17 Units on a scale | Standard Deviation 1.25 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 97 | -0.19 Units on a scale | Standard Deviation 1.31 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 98 | -0.25 Units on a scale | Standard Deviation 1.16 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 99 | -0.21 Units on a scale | Standard Deviation 1.47 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 100 | -0.50 Units on a scale | Standard Deviation 1.38 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 101 | -0.36 Units on a scale | Standard Deviation 1.38 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 102 | -0.75 Units on a scale | Standard Deviation 1.71 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 103 | -0.33 Units on a scale | Standard Deviation 1.54 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 105 | -1.00 Units on a scale | Standard Deviation 1.41 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 106 | -1.00 Units on a scale | Standard Deviation 1.41 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 107 | -1.00 Units on a scale | Standard Deviation 1.41 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 108 | -0.75 Units on a scale | Standard Deviation 1.5 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 109 | -0.60 Units on a scale | Standard Deviation 1.52 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 110 | -0.42 Units on a scale | Standard Deviation 1.43 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 111 | -0.50 Units on a scale | Standard Deviation 1.5 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 112 | -0.13 Units on a scale | Standard Deviation 0.63 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 113 | 0.13 Units on a scale | Standard Deviation 0.63 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 115 | 0.25 Units on a scale | Standard Deviation 0.35 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 116 | 0.50 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 117 | 0.25 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 118 | -0.25 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 120 | 0.00 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 121 | 0.00 Units on a scale | Standard Deviation 1.41 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 122 | 0.00 Units on a scale | Standard Deviation 1.41 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 123 | -0.75 Units on a scale | Standard Deviation 1.77 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 124 | 0.50 Units on a scale | — |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 125 | 0.50 Units on a scale | — |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 1 | 0.01 Units on a scale | Standard Deviation 1.13 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 2 | -0.07 Units on a scale | Standard Deviation 1.18 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 3 | 0.15 Units on a scale | Standard Deviation 1.33 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 4 | -0.28 Units on a scale | Standard Deviation 1.4 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 5 | -0.11 Units on a scale | Standard Deviation 1.49 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 6 | -0.37 Units on a scale | Standard Deviation 1.67 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 1 | 0.08 Units on a scale | Standard Deviation 0.69 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 2 | 0.02 Units on a scale | Standard Deviation 0.78 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 3 | 0.02 Units on a scale | Standard Deviation 0.86 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 4 | -0.06 Units on a scale | Standard Deviation 0.86 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 5 | -0.09 Units on a scale | Standard Deviation 0.84 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 7 | -0.11 Units on a scale | Standard Deviation 0.86 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 8 | -0.13 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 9 | -0.15 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 10 | -0.20 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 11 | -0.15 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 12 | -0.17 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 13 | -0.24 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 14 | -0.23 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 15 | -0.27 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 16 | -0.37 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 17 | -0.32 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 18 | -0.33 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 19 | -0.33 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 96 | -0.28 Units on a scale | Standard Deviation 1.28 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 21 | -0.37 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 22 | -0.37 Units on a scale | Standard Deviation 1.15 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 23 | -0.30 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 24 | -0.38 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 25 | -0.49 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 26 | -0.43 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 27 | -0.41 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 28 | -0.52 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 29 | -0.43 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 30 | -0.43 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 31 | -0.32 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 32 | -0.30 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 33 | -0.19 Units on a scale | Standard Deviation 1.12 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 34 | -0.35 Units on a scale | Standard Deviation 1.12 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 35 | -0.46 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 36 | -0.35 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 37 | -0.46 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 38 | -0.38 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 39 | -0.27 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 40 | -0.38 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 41 | -0.44 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 42 | -0.44 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 43 | -0.39 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 44 | -0.38 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 45 | -0.30 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 46 | -0.25 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 47 | -0.44 Units on a scale | Standard Deviation 0.88 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 48 | -0.29 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 49 | -0.38 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 50 | -0.39 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 51 | -0.30 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 52 | -0.32 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 53 | -0.37 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 54 | -0.41 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 55 | -0.40 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 56 | -0.26 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 57 | -0.35 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 58 | -0.33 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 59 | -0.31 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 60 | -0.42 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 61 | -0.35 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 62 | -0.23 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 63 | -0.22 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 64 | -0.19 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 65 | -0.23 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 66 | -0.29 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 67 | -0.48 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 68 | -0.34 Units on a scale | Standard Deviation 0.82 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 69 | -0.34 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 70 | -0.26 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 71 | -0.23 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 72 | -0.48 Units on a scale | Standard Deviation 0.87 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 73 | -0.43 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 74 | -0.42 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 75 | -0.32 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 76 | -0.31 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 77 | -0.40 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 78 | -0.52 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 79 | -0.08 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 80 | -0.48 Units on a scale | Standard Deviation 0.87 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 81 | -0.44 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 82 | -0.39 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 83 | -0.25 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 2 | -0.07 Units on a scale | Standard Deviation 1.16 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 3 | -0.14 Units on a scale | Standard Deviation 1.12 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 4 | -0.39 Units on a scale | Standard Deviation 1.15 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 5 | -0.25 Units on a scale | Standard Deviation 1.44 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 6 | -0.23 Units on a scale | Standard Deviation 1.53 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 2 | 0.10 Units on a scale | Standard Deviation 0.68 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 3 | 0.22 Units on a scale | Standard Deviation 0.78 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 5 | 0.26 Units on a scale | Standard Deviation 0.84 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 6 | 0.27 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 7 | 0.29 Units on a scale | Standard Deviation 0.88 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 9 | 0.38 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 11 | 0.50 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 12 | 0.47 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 16 | 0.22 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 17 | 0.28 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 19 | 0.26 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 21 | 0.26 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 22 | 0.21 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 26 | 0.17 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 28 | 0.16 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 29 | 0.16 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 31 | 0.12 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 32 | 0.20 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 33 | 0.18 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 34 | 0.21 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 38 | 0.18 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 39 | 0.31 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 41 | 0.24 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 46 | 0.29 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 48 | 0.32 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 49 | 0.24 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 54 | 0.28 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 55 | 0.26 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 56 | 0.26 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 58 | 0.19 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 61 | 0.33 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 63 | 0.44 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 64 | 0.36 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 65 | 0.27 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 66 | 0.32 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 67 | 0.28 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 68 | 0.35 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 69 | 0.44 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 70 | 0.33 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 71 | 0.50 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 72 | 0.17 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 74 | 0.30 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 75 | 0.26 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 76 | 0.23 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 77 | 0.20 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 81 | -0.12 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 84 | 0.19 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 87 | -0.11 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 88 | 0.06 Units on a scale | Standard Deviation 1.12 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 90 | 0.37 Units on a scale | Standard Deviation 0.83 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 91 | 0.33 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 92 | 0.20 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 93 | 0.35 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 94 | 0.50 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 95 | 0.48 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 96 | 0.51 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 97 | 0.33 Units on a scale | Standard Deviation 1.18 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 98 | 0.38 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 99 | 0.11 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 100 | 0.27 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 101 | 0.20 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 103 | 0.47 Units on a scale | Standard Deviation 1.29 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 106 | -0.20 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 107 | -0.30 Units on a scale | Standard Deviation 0.62 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 108 | -0.15 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 109 | 0.16 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 110 | 0.33 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 111 | -0.04 Units on a scale | Standard Deviation 0.86 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 119 | -0.25 Units on a scale | Standard Deviation 0.35 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 79 | 0.32 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 99 | -0.43 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 100 | -0.58 Units on a scale | Standard Deviation 0.86 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 101 | -0.50 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 102 | -0.50 Units on a scale | Standard Deviation 0.41 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 103 | -0.75 Units on a scale | Standard Deviation 0.42 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 104 | -0.80 Units on a scale | Standard Deviation 0.27 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 105 | -0.63 Units on a scale | Standard Deviation 0.48 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 122 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 125 | 0.50 Units on a scale | — |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 1 | -0.21 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 1 | 0.13 Units on a scale | Standard Deviation 0.76 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 15 | 0.29 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 18 | 0.23 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 20 | 0.24 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 23 | 0.18 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 43 | 0.17 Units on a scale | Standard Deviation 1.13 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 44 | 0.22 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 45 | 0.26 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 47 | 0.20 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 80 | 0.30 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 82 | 0.02 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 83 | 0.13 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 85 | 0.05 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 1 | 0.19 Units on a scale | Standard Deviation 0.86 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 3 | -0.05 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 7 | -0.23 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 8 | -0.21 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 9 | -0.18 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 13 | -0.26 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 14 | -0.28 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 20 | -0.26 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 21 | -0.25 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 22 | -0.28 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 23 | -0.24 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 24 | -0.21 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 25 | -0.20 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 26 | -0.17 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 29 | -0.27 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 30 | -0.15 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 31 | -0.16 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 32 | -0.19 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 33 | -0.18 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 36 | -0.21 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 37 | -0.18 Units on a scale | Standard Deviation 1.18 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 38 | -0.32 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 39 | -0.28 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 40 | -0.19 Units on a scale | Standard Deviation 0.87 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 41 | -0.25 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 42 | -0.16 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 43 | -0.24 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 44 | -0.24 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 45 | -0.14 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 46 | -0.15 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 47 | -0.22 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 48 | -0.14 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 49 | -0.22 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 50 | -0.18 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 51 | -0.13 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 52 | -0.15 Units on a scale | Standard Deviation 0.83 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 53 | -0.20 Units on a scale | Standard Deviation 0.82 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 54 | -0.22 Units on a scale | Standard Deviation 0.87 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 55 | -0.34 Units on a scale | Standard Deviation 0.8 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 56 | -0.19 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 57 | -0.19 Units on a scale | Standard Deviation 0.76 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 58 | -0.32 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 59 | -0.25 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 60 | -0.27 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 61 | -0.28 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 62 | -0.16 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 63 | -0.12 Units on a scale | Standard Deviation 0.82 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 64 | -0.15 Units on a scale | Standard Deviation 0.83 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 65 | -0.31 Units on a scale | Standard Deviation 0.84 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 66 | -0.25 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 67 | -0.18 Units on a scale | Standard Deviation 0.86 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 68 | -0.15 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 69 | -0.13 Units on a scale | Standard Deviation 0.83 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 70 | -0.14 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 71 | -0.10 Units on a scale | Standard Deviation 0.88 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 72 | -0.24 Units on a scale | Standard Deviation 0.85 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 84 | -0.30 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 85 | -0.32 Units on a scale | Standard Deviation 1.25 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 87 | -0.33 Units on a scale | Standard Deviation 1.18 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 88 | -0.46 Units on a scale | Standard Deviation 1.26 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 89 | -0.36 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 90 | -0.29 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 91 | -0.27 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 92 | -0.35 Units on a scale | Standard Deviation 1.27 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 93 | -0.55 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 94 | -0.40 Units on a scale | Standard Deviation 0.81 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 52 | 0.27 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 53 | 0.24 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 57 | 0.37 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 59 | 0.32 Units on a scale | Standard Deviation 0.84 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 60 | 0.35 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 62 | 0.45 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 73 | 0.41 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 78 | 0.31 Units on a scale | Standard Deviation 0.94 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 54 | -0.07 Units on a scale | Standard Deviation 1.21 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 72 | -1.50 Units on a scale | Standard Deviation 1.41 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 51 | 0.06 Units on a scale | Standard Deviation 1.04 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 31 | -0.12 Units on a scale | Standard Deviation 1.05 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 92 | 1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 56 | 0.53 Units on a scale | Standard Deviation 1.1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 32 | -0.30 Units on a scale | Standard Deviation 1.1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 57 | 0.24 Units on a scale | Standard Deviation 1.08 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 58 | 0.35 Units on a scale | Standard Deviation 1.4 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 58 | -0.50 Units on a scale | Standard Deviation 1.15 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 59 | 0.35 Units on a scale | Standard Deviation 1.4 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 35 | 0.05 Units on a scale | Standard Deviation 1.06 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 70 | 0.00 Units on a scale | Standard Deviation 1.8 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 62 | 0.72 Units on a scale | Standard Deviation 1.36 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 66 | 0.50 Units on a scale | Standard Deviation 1.23 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 67 | 0.40 Units on a scale | Standard Deviation 1.36 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 68 | 0.40 Units on a scale | Standard Deviation 1.43 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 69 | 0.73 Units on a scale | Standard Deviation 1.55 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 36 | -0.35 Units on a scale | Standard Deviation 1.01 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 73 | -1.80 Units on a scale | Standard Deviation 1.13 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 59 | -0.63 Units on a scale | Standard Deviation 0.75 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 37 | -0.10 Units on a scale | Standard Deviation 1.04 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 88 | 0.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 38 | -0.05 Units on a scale | Standard Deviation 1.01 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 60 | -0.50 Units on a scale | Standard Deviation 1.08 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 39 | -0.22 Units on a scale | Standard Deviation 1.06 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 71 | 0.00 Units on a scale | Standard Deviation 0.87 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 40 | -0.39 Units on a scale | Standard Deviation 0.81 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 61 | -0.20 Units on a scale | Standard Deviation 1.15 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 41 | -0.19 Units on a scale | Standard Deviation 0.89 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 91 | 0.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 42 | -0.41 Units on a scale | Standard Deviation 0.74 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 62 | -0.40 Units on a scale | Standard Deviation 1.47 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 1 | 0.23 Units on a scale | Standard Deviation 0.79 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 14 | 0.61 Units on a scale | Standard Deviation 1.1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 43 | -0.22 Units on a scale | Standard Deviation 0.95 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 16 | 0.67 Units on a scale | Standard Deviation 1.11 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 72 | -1.00 Units on a scale | Standard Deviation 0.71 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 18 | 0.62 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 44 | 0.00 Units on a scale | Standard Deviation 0.98 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 20 | 0.54 Units on a scale | Standard Deviation 1.08 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 21 | 0.39 Units on a scale | Standard Deviation 1.05 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 63 | -0.10 Units on a scale | Standard Deviation 1.34 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 45 | -0.07 Units on a scale | Standard Deviation 0.78 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 89 | 0.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 44 | 0.29 Units on a scale | Standard Deviation 0.86 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 46 | -0.07 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 46 | 0.47 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 64 | 0.38 Units on a scale | Standard Deviation 1.44 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 47 | 0.45 Units on a scale | Standard Deviation 0.85 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 47 | -0.15 Units on a scale | Standard Deviation 0.9 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 93 | 0.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 82 | -0.80 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 48 | -0.18 Units on a scale | Standard Deviation 0.98 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 84 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 65 | 0.17 Units on a scale | Standard Deviation 1.76 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 85 | -0.80 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 49 | -0.72 Units on a scale | Standard Deviation 0.75 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 1 | 0.14 Units on a scale | Standard Deviation 0.9 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 85 | 1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 3 | 0.01 Units on a scale | Standard Deviation 0.92 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 4 | 0.01 Units on a scale | Standard Deviation 1.02 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 50 | -0.19 Units on a scale | Standard Deviation 0.7 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 7 | 0.03 Units on a scale | Standard Deviation 1.08 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 66 | 0.25 Units on a scale | Standard Deviation 1.19 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 51 | -0.50 Units on a scale | Standard Deviation 0.78 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 12 | -0.10 Units on a scale | Standard Deviation 1.13 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 86 | 0.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 13 | -0.03 Units on a scale | Standard Deviation 1.02 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 52 | -0.36 Units on a scale | Standard Deviation 0.63 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 14 | -0.17 Units on a scale | Standard Deviation 1.18 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 67 | 0.13 Units on a scale | Standard Deviation 1.44 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 20 | -0.22 Units on a scale | Standard Deviation 1.02 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 53 | -0.33 Units on a scale | Standard Deviation 0.61 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 21 | -0.32 Units on a scale | Standard Deviation 1.08 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 90 | 0.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 22 | -0.11 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 54 | -0.21 Units on a scale | Standard Deviation 0.7 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 23 | -0.19 Units on a scale | Standard Deviation 1.04 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 68 | -0.25 Units on a scale | Standard Deviation 1.55 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 24 | -0.43 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 55 | -0.30 Units on a scale | Standard Deviation 0.76 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 25 | -0.24 Units on a scale | Standard Deviation 1.07 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 87 | 0.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 27 | -0.15 Units on a scale | Standard Deviation 1.17 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 56 | -0.33 Units on a scale | Standard Deviation 0.68 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 29 | -0.04 Units on a scale | Standard Deviation 0.92 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 69 | -0.17 Units on a scale | Standard Deviation 1.89 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 30 | -0.28 Units on a scale | Standard Deviation 1.12 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 57 | -0.40 Units on a scale | Standard Deviation 0.65 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 1 | -0.01 Units on a scale | Standard Deviation 0.96 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 4 | -0.10 Units on a scale | Standard Deviation 0.93 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 2 | -0.31 Units on a scale | Standard Deviation 1.18 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 2 | 0.46 Units on a scale | Standard Deviation 1.22 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 3 | -0.13 Units on a scale | Standard Deviation 1.32 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 4 | 0.45 Units on a scale | Standard Deviation 0.88 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 4 | -0.45 Units on a scale | Standard Deviation 1.17 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 43 | -0.13 Units on a scale | Standard Deviation 0.92 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 5 | -0.27 Units on a scale | Standard Deviation 1.32 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 2 | 0.03 Units on a scale | Standard Deviation 0.91 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Survival Follow-Up Month 6 | -0.29 Units on a scale | Standard Deviation 1.26 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 5 | -0.09 Units on a scale | Standard Deviation 0.99 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 2 | 0.31 Units on a scale | Standard Deviation 0.84 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 6 | -0.08 Units on a scale | Standard Deviation 0.98 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 3 | 0.32 Units on a scale | Standard Deviation 0.76 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 5 | 0.00 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 5 | 0.42 Units on a scale | Standard Deviation 0.92 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 73 | -0.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 6 | 0.51 Units on a scale | Standard Deviation 0.95 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 6 | 0.03 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 8 | -0.14 Units on a scale | Standard Deviation 1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 9 | -0.01 Units on a scale | Standard Deviation 1.07 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 11 | 0.60 Units on a scale | Standard Deviation 1.06 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 7 | -0.06 Units on a scale | Standard Deviation 1.01 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 15 | 0.71 Units on a scale | Standard Deviation 1.02 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 10 | -0.07 Units on a scale | Standard Deviation 1.01 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 44 | -0.16 Units on a scale | Standard Deviation 0.89 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 17 | 0.68 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 11 | 0.01 Units on a scale | Standard Deviation 0.96 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 19 | 0.54 Units on a scale | Standard Deviation 0.95 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 8 | -0.21 Units on a scale | Standard Deviation 1.04 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 63 | 0.50 Units on a scale | Standard Deviation 1.27 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 22 | 0.41 Units on a scale | Standard Deviation 1.05 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 25 | 0.20 Units on a scale | Standard Deviation 0.91 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 15 | -0.19 Units on a scale | Standard Deviation 1.19 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 26 | 0.30 Units on a scale | Standard Deviation 1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 27 | 0.30 Units on a scale | Standard Deviation 0.92 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 9 | -0.13 Units on a scale | Standard Deviation 1.23 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 28 | 0.22 Units on a scale | Standard Deviation 1.01 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 16 | -0.16 Units on a scale | Standard Deviation 1.2 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 30 | 0.27 Units on a scale | Standard Deviation 1.02 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 45 | -0.14 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 31 | 0.26 Units on a scale | Standard Deviation 1.04 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 17 | -0.14 Units on a scale | Standard Deviation 1.13 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 10 | -0.07 Units on a scale | Standard Deviation 1.17 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 33 | 0.19 Units on a scale | Standard Deviation 1.14 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 18 | -0.07 Units on a scale | Standard Deviation 1.13 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 34 | 0.30 Units on a scale | Standard Deviation 1.02 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 36 | 0.34 Units on a scale | Standard Deviation 1.14 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 37 | 0.10 Units on a scale | Standard Deviation 1.07 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 81 | -0.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 38 | 0.51 Units on a scale | Standard Deviation 0.99 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 19 | -0.16 Units on a scale | Standard Deviation 1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 26 | -0.13 Units on a scale | Standard Deviation 0.91 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 41 | 0.18 Units on a scale | Standard Deviation 0.85 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 43 | 0.41 Units on a scale | Standard Deviation 0.91 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 45 | 0.31 Units on a scale | Standard Deviation 0.9 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 11 | -0.15 Units on a scale | Standard Deviation 1.17 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 46 | -0.03 Units on a scale | Standard Deviation 1.23 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 48 | 0.29 Units on a scale | Standard Deviation 0.91 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 28 | -0.07 Units on a scale | Standard Deviation 0.91 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 52 | 0.29 Units on a scale | Standard Deviation 0.9 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 53 | 0.30 Units on a scale | Standard Deviation 0.85 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 33 | -0.18 Units on a scale | Standard Deviation 1.11 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 54 | 0.40 Units on a scale | Standard Deviation 0.95 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 12 | -0.11 Units on a scale | Standard Deviation 1.09 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 55 | 0.44 Units on a scale | Standard Deviation 1.02 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 34 | -0.17 Units on a scale | Standard Deviation 1.18 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 64 | 0.00 Units on a scale | Standard Deviation 1.87 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 60 | 0.50 Units on a scale | Standard Deviation 1.51 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 13 | -0.04 Units on a scale | Standard Deviation 1.11 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 61 | 0.60 Units on a scale | Standard Deviation 1.4 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 73 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 63 | 0.56 Units on a scale | Standard Deviation 1.35 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 47 | -0.12 Units on a scale | Standard Deviation 1.23 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 64 | -0.50 Units on a scale | Standard Deviation 1.91 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 74 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 65 | 0.07 Units on a scale | Standard Deviation 1.68 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 14 | -0.18 Units on a scale | Standard Deviation 1.08 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 75 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 74 | -0.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 76 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 15 | -0.05 Units on a scale | Standard Deviation 1.1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 70 | 0.73 Units on a scale | Standard Deviation 1.55 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 77 | -1.50 Units on a scale | Standard Deviation 0 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 71 | 0.60 Units on a scale | Standard Deviation 1.51 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 48 | 0.14 Units on a scale | Standard Deviation 1.21 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 72 | 0.60 Units on a scale | Standard Deviation 1.44 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 78 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 74 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 16 | -0.25 Units on a scale | Standard Deviation 1.09 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 75 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 79 | -0.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 76 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 65 | 0.83 Units on a scale | Standard Deviation 1.04 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 77 | -1.50 Units on a scale | Standard Deviation 1.56 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 78 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 79 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 80 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 80 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 81 | -0.80 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 83 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 17 | -0.21 Units on a scale | Standard Deviation 1.01 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 81 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 87 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 49 | -0.56 Units on a scale | Standard Deviation 1.36 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 89 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 82 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 90 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 18 | -0.33 Units on a scale | Standard Deviation 1.09 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 91 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 83 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 92 | -0.80 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 79 | 1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 93 | -0.80 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 84 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 19 | -0.40 Units on a scale | Standard Deviation 0.89 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 85 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 50 | -0.19 Units on a scale | Standard Deviation 1.16 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 86 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 20 | -0.31 Units on a scale | Standard Deviation 0.9 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 87 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 66 | 0.63 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 88 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 21 | -0.33 Units on a scale | Standard Deviation 0.96 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 89 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 51 | -0.40 Units on a scale | Standard Deviation 1.2 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 90 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 22 | -0.24 Units on a scale | Standard Deviation 0.97 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 91 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 75 | -0.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 92 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 23 | -0.41 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Week 93 | -1.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 52 | -0.21 Units on a scale | Standard Deviation 1.07 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 24 | -0.54 Units on a scale | Standard Deviation 1.04 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 67 | 0.38 Units on a scale | Standard Deviation 1.38 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 25 | -0.47 Units on a scale | Standard Deviation 1.05 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 53 | -0.17 Units on a scale | Standard Deviation 1.33 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 26 | -0.34 Units on a scale | Standard Deviation 1.02 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 83 | 0.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 27 | -0.48 Units on a scale | Standard Deviation 0.98 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 1 | 0.60 Units on a scale | Standard Deviation 1.14 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 68 | 0.13 Units on a scale | Standard Deviation 1.49 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 28 | -0.43 Units on a scale | Standard Deviation 0.84 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 3 | 0.61 Units on a scale | Standard Deviation 1.19 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 55 | 0.10 Units on a scale | Standard Deviation 1.34 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 29 | -0.46 Units on a scale | Standard Deviation 0.91 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 5 | 0.48 Units on a scale | Standard Deviation 1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 76 | -0.50 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Survival Follow-Up Month 6 | 0.54 Units on a scale | Standard Deviation 0.97 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 30 | -0.46 Units on a scale | Standard Deviation 1.07 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 56 | 0.17 Units on a scale | Standard Deviation 1.13 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 31 | -0.38 Units on a scale | Standard Deviation 0.77 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 71 | 0.33 Units on a scale | Standard Deviation 1.04 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 84 | 1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 69 | 0.17 Units on a scale | Standard Deviation 1.61 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 32 | -0.12 Units on a scale | Standard Deviation 0.99 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 49 | 0.00 Units on a scale | Standard Deviation 1.3 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 57 | 0.00 Units on a scale | Standard Deviation 1.27 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 50 | 0.43 Units on a scale | Standard Deviation 0.88 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 33 | -0.52 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 80 | 1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 34 | -0.33 Units on a scale | Standard Deviation 1.03 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 58 | 0.13 Units on a scale | Standard Deviation 1.31 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 35 | 0.00 Units on a scale | Standard Deviation 1.22 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 70 | 0.17 Units on a scale | Standard Deviation 1.61 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 36 | -0.20 Units on a scale | Standard Deviation 1.01 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 59 | 0.13 Units on a scale | Standard Deviation 1.6 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 37 | -0.45 Units on a scale | Standard Deviation 1.11 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 4 | 0.45 Units on a scale | Standard Deviation 0.84 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 7 | 0.60 Units on a scale | Standard Deviation 1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 77 | -0.50 Units on a scale | Standard Deviation 2.83 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 8 | 0.53 Units on a scale | Standard Deviation 1.02 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 9 | 0.62 Units on a scale | Standard Deviation 1.07 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 38 | -0.03 Units on a scale | Standard Deviation 0.89 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 10 | 0.75 Units on a scale | Standard Deviation 1.13 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 12 | 0.74 Units on a scale | Standard Deviation 1.08 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 1 | 0.22 Units on a scale | Standard Deviation 0.87 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 13 | 0.76 Units on a scale | Standard Deviation 1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 60 | 0.38 Units on a scale | Standard Deviation 1.18 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 23 | 0.41 Units on a scale | Standard Deviation 1.06 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 2 | -0.16 Units on a scale | Standard Deviation 0.96 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 24 | 0.31 Units on a scale | Standard Deviation 1.01 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 39 | -0.17 Units on a scale | Standard Deviation 1 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 3 | -0.08 Units on a scale | Standard Deviation 0.87 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 29 | 0.33 Units on a scale | Standard Deviation 0.98 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 82 | 1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 32 | 0.38 Units on a scale | Standard Deviation 1.06 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 4 | -0.07 Units on a scale | Standard Deviation 0.79 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 35 | 0.46 Units on a scale | Standard Deviation 0.96 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 40 | -0.50 Units on a scale | Standard Deviation 0.9 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 5 | -0.02 Units on a scale | Standard Deviation 0.65 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 39 | 0.26 Units on a scale | Standard Deviation 0.83 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 61 | 0.80 Units on a scale | Standard Deviation 1.2 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 40 | 0.04 Units on a scale | Standard Deviation 0.79 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Chest Pain, Survival Follow-Up Month 6 | 0.02 Units on a scale | Standard Deviation 0.78 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 42 | 0.08 Units on a scale | Standard Deviation 0.7 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 41 | -0.22 Units on a scale | Standard Deviation 0.77 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 86 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Dyspnoea, Week 88 | -1.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 1 | 0.04 Units on a scale | Standard Deviation 0.73 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 78 | 0.00 Units on a scale | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 2 | 0.04 Units on a scale | Standard Deviation 0.84 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 42 | -0.41 Units on a scale | Standard Deviation 0.97 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 3 | -0.09 Units on a scale | Standard Deviation 0.93 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale | Cough, Week 62 | 0.50 Units on a scale | Standard Deviation 1.62 |
Secondary
Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population
DOR,defined for participants with objective response (OR) as time from 1st documented OR to documented disease progression as determined by investigator using RECIST v1.1,or death from any cause,whichever occurs 1st.ITT defined as all randomized participants,regardless of receipt of assigned treatment.ITT-WT defined as ITT population excluding participants with activating EGFR mutation or ALK translocation.PD-L1 expression population is defined as one of following:PD-L1 IHC TC1/2/3 or IC1/2/3 population,defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue;PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue;PD-L1 IHC TC3 or IC3 population,defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue.PD-L1 expression WT is defined as PD-L1 expression population excluding participants with activating EGFR mutation or ALK translocation.
Time frame: Up to approximately 35 months after first subject enrolled
Population: ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-l1 Expression WT Population
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population | ITT Population | 6.2 Months |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population | ITT-WT Population | 6.7 Months |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT Population | 7.2 Months |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT WT Population | 7.2 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT WT Population | 5.0 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population | ITT Population | 5.4 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT Population | 5.0 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population | ITT-WT Population | 5.4 Months |
Comparison: ITT Populationp-value: 0.000295% CI: [0.473, 0.797]Log Rank
Comparison: ITT-WT Populationp-value: 0.000295% CI: [0.458, 0.785]Log Rank
Comparison: TC1/2/3 or IC1/2/3 ITT Populationp-value: 0.001195% CI: [0.379, 0.791]Log Rank
Comparison: TC1/2/3 or IC1/2/3 ITT WT Populationp-value: 0.001495% CI: [0.381, 0.798]Log Rank
Secondary
Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population
The OS rate at the 1- and 2-year landmark time points after randomization.
Time frame: Up to 41 months after first patient enrolled, years 1 and 2 reported
Population: The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation. The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population | Event Free Rate (%) at Year 2 ITT WT | 40.43 Percentage of participants |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population | Event Free Rate (%) at Year 1 ITT WT | 62.02 Percentage of participants |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population | Event Free Rate (%) at Year 2 ITT | 39.73 Percentage of participants |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population | Event Free Rate (%) at Year 1 ITT | 61.65 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population | Event Free Rate (%) at Year 2 ITT | 32.21 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population | Event Free Rate (%) at Year 1 ITT WT | 54.56 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population | Event Free Rate (%) at Year 1 ITT | 54.47 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population | Event Free Rate (%) at Year 2 ITT WT | 32.36 Percentage of participants |
Comparison: Event Free Rate (%) at Year 1 ITT WT Populationp-value: 0.064795% CI: [-0.45, 15.37]Z-test
Comparison: Event Free Rate (%) at Year 2 ITT WT Populationp-value: 0.051695% CI: [-0.06, 16.19]Z-test
Comparison: Event Free Rate (%) at Year 1 ITT Populationp-value: 0.068395% CI: [-0.54, 14.91]Z-test
Comparison: Event Free Rate (%) at Year 2 ITT Populationp-value: 0.062595% CI: [-0.39, 15.44]Z-test
Secondary
Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population
The OS rate at the 1- and 2-year landmark time points after randomization in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Time frame: Up to 35 months after first patient enrolled, years 1 and 2 reported
Population: PD-L1 Expression Population and PD-L1 Expression WT Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population | Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT | 68.56 Percentage of participants |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population | Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT | 44.63 Percentage of participants |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population | Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT WT | 68.84 Percentage of participants |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population | Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT WT | 44.02 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population | Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT WT | 35.33 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population | Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT | 61.86 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population | Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT WT | 62.51 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population | Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT | 35.98 Percentage of participants |
Comparison: Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITTp-value: 0.238595% CI: [-4.44, 17.83]Z-test
Comparison: Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITTp-value: 0.27195% CI: [-6.75, 24.03]Z-test
Comparison: Event Free Rate (%) Year 1 TC1/2/3 or IC1/2/3 ITT WTp-value: 0.273395% CI: [-5, 17.67]Z-test
Comparison: Event Free Rate (%) Year 2 TC1/2/3 or IC1/2/3 ITT WTp-value: 0.290995% CI: [-7.44, 24.81]Z-test
Secondary
Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm
Predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.
Time frame: Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)
Population: The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm | Cycle 1 Day 1 | 392 mcg/mL | Standard Deviation 114 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm | Cycle 3 Day 1 | 454 mcg/mL | Standard Deviation 170 |
Secondary
Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel
Predose samples will be collected on the same day of treatment administration.
Time frame: Cycle 1 Day 21, Cycle 2 Day 21, Cycle 3 Day 21, and Cycle 7 Day 21 (Cycle length = 21 days)
Population: The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel | Cycle 1 Day 21 | 70.9 mcg/mL | Standard Deviation 35.1 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel | Cycle 2 Day 21 | 111 mcg/mL | Standard Deviation 52.2 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel | Cycle 3 Day 21 | 134 mcg/mL | Standard Deviation 57.8 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel | Cycle 7 Day 21 | 218 mcg/mL | Standard Deviation 93.7 |
Secondary
OS as Determined by the Investigator Using Recist v1.1 in the ITT Population
OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.
Time frame: Up to approximately 41 months after first subject enrolled
Population: The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | OS as Determined by the Investigator Using Recist v1.1 in the ITT Population | 17.0 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | OS as Determined by the Investigator Using Recist v1.1 in the ITT Population | 13.5 Months |
p-value: 0.073295% CI: [0.689, 1.017]Log Rank
Secondary
OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population
OS is defined as the time between the date of randomization and date of death from any cause in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Time frame: Up to approximately 35 months after first patient enrolled
Population: PD-L1 Expression Population and PD-L1 Expression WT Population
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT Population | 21.2 Months |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 WT ITT Population | 21.2 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT Population | 16.9 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 WT ITT Population | 16.9 Months |
Comparison: TC1/2/3 or IC1/2/3 ITT Populationp-value: 0.08395% CI: [0.545, 1.039]Log Rank
Comparison: TC1/2/3 or IC1/2/3 WT ITT Populationp-value: 0.081395% CI: [0.536, 1.038]Log Rank
Secondary
Percentage of Participants With Adverse Events
Percentage of participants with at least one adverse event. Adverse event onset date before cross over.
Time frame: Up to approximately 69 months after first patient enrolled
Population: The safety-evaluable population included all treated participants, defined as randomized participants who received any protocol treatment. For the safety analyses, participants were grouped according to whether any full or partial dose of atezolizumab was received, including when atezolizumab was received in error. Specifically, for participants randomized to the CnP arm, if atezolizumab was received in error, the participants were grouped to the Atezo+CnP arm for the safety analyses.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Percentage of Participants With Adverse Events | 99.6 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Percentage of Participants With Adverse Events | 98.7 Percentage of participants |
Secondary
Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
ORR (confirmation not required) is defined as proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by investigator in ITT population, PD-L1 Expression population, and PD-L1 Expression WT population. ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. PD-L1 expression WT population is defined as PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Time frame: Up to approximately 35 months after first subject enrolled
Population: ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | ITT Population | 59.1 Percentage of participants |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT WT Population | 65.6 Percentage of participants |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT Population | 64.6 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | ITT Population | 42.2 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT WT Population | 46.2 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT Population | 45.0 Percentage of participants |
Comparison: ITT Populationp-value: <0.000195% CI: [8.9, 24.88]Cochran-Mantel-Haenszel
Comparison: TC1/2/3 or IC1/2/3 ITT WT Population95% CI: [1.38, 3.56]
Comparison: TC1/2/3 or IC1/2/3 ITT Populationp-value: 0.000795% CI: [1.39, 3.51]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population
ORR (confirmation not required) is defined as the proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by the investigator in the ITT-WT population.
Time frame: Up to approximately 41 months after first subject enrolled
Population: The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population | 60.2 Percentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population | 41.0 Percentage of participants |
p-value: <0.000195% CI: [11.05, 27.37]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Baseline prevalence and post-baseline incidence of anti-drug antibodies (ADA) to Atezolizumab in the Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B Carboplatin+nab-paclitaxel Crossover Participants
Time frame: Up to approximately 35 months after first subject enrolled
Population: The baseline ADA-evaluable population included participants who had a baseline ADA result. The post-baseline ADA-evaluable population included participants who had at least one post-baseline ADA result and who had received at least one dose of study treatment. The ADA-evaluable WT population was defined as the ADA-evaluable population excluding participants with an activating EGFR mutation or ALK translocation.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab | Baseline | 3.1 Perecentage of participants |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab | Post-baseline | 22.4 Perecentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab | Baseline | 4.8 Perecentage of participants |
| Arm B (Nab-Paclitaxel+Carboplatin) | Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab | Post-baseline | 23.5 Perecentage of participants |
Secondary
PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Time frame: Up to approximately 35 months after first subject enrolled
Population: ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | ITT Population | 7.0 Months |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT Population | 7.5 Months |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3-WT ITT Population | 7.5 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | ITT Population | 5.6 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3 ITT Population | 5.7 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population | TC1/2/3 or IC1/2/3-WT ITT Population | 5.9 Months |
Comparison: ITT Populationp-value: <0.000195% CI: [0.545, 0.768]Log Rank
Comparison: TC1/2/3 or IC1/2/3-WT ITT Populationp-value: <0.000195% CI: [0.432, 0.728]Log Rank
Comparison: TC1/2/3 or IC1/2/3 ITT Populationp-value: <0.000195% CI: [0.425, 0.708]Log Rank
Secondary
Plasma Concentrations of Carboplatin
Time frame: Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 hour after carboplatin infusion (infusion duration=15 to 30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)
Population: The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 1 Day 1 Before End of Infusion | 20,500 ng/mL | Standard Deviation 7500 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 1 Day 1 Post Infusion | 11,900 ng/mL | Standard Deviation 3100 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 3 Day 1 Pre-dose | 169 ng/mL | Standard Deviation 63.8 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 3 Day 1 Before End of Infusion | 15,300 ng/mL | Standard Deviation 6600 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 3 Day 1 Post Infusion | 11,400 ng/mL | Standard Deviation 3060 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 1 Day 1 Pre-dose | NA ng/mL | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 3 Day 1 Post Infusion | 13,400 ng/mL | Standard Deviation 6650 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 1 Day 1 Before End of Infusion | 17,000 ng/mL | Standard Deviation 5200 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 3 Day 1 Before End of Infusion | 17,800 ng/mL | Standard Deviation 7550 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 1 Day 1 Post Infusion | 12,400 ng/mL | Standard Deviation 3800 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 1 Day 1 Pre-dose | NA ng/mL | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Carboplatin | Cycle 3 Day 1 Pre-dose | 160 ng/mL | Standard Deviation 48.8 |
Secondary
Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel
Time frame: Predose (same day of treatment administration), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after nab-paclitaxel infusion (infusion duration=30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)
Population: The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 1 Day 1 Pre-dose | NA ng/mL | — |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 3 Day 1 Before End of Infusion | 4480 ng/mL | Standard Deviation 3520 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 3 Day 1 Post Infusion | 357 ng/mL | Standard Deviation 253 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 1 Day 1 Before End of Infusion | 3520 ng/mL | Standard Deviation 2210 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 1 Day 1 Post Infusion | 307 ng/mL | Standard Deviation 153 |
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 3 Day 1 Pre-dose | NA ng/mL | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 3 Day 1 Post Infusion | 447 ng/mL | Standard Deviation 322 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 1 Day 1 Pre-dose | NA ng/mL | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 3 Day 1 Pre-dose | NA ng/mL | — |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 1 Day 1 Post Infusion | 417 ng/mL | Standard Deviation 217 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 3 Day 1 Before End of Infusion | 2030 ng/mL | Standard Deviation 1690 |
| Arm B (Nab-Paclitaxel+Carboplatin) | Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel | Cycle 1 Day 1 Before End of Infusion | 2530 ng/mL | Standard Deviation 1420 |
Secondary
Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population
Defined as time from randomization to confirmed deterioration (10-point change) on the combined European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C30) and supplemental lung cancer module (EORTC QLQ-LC13) symptom subscales.
Time frame: Up to approximately 35 months after first subject enrolled
Population: The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population | 2.2 Months |
| Arm B (Nab-Paclitaxel+Carboplatin) | Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population | 1.9 Months |
p-value: 0.334295% CI: [0.711, 1.123]Log Rank